{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:31:51Z","timestamp":1786379511908,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ccell.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:14:45Z","timestamp":1786374885000},"page":"1525-1532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-026X","authenticated-orcid":false,"given":"Anna","family":"Skwarska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.07.004_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/bloodadvances.2024014446","article-title":"Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2026.07.004_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.07.004_bib3","article-title":"Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia","author":"Minihane","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2026.07.004_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.07.004_bib5","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.07.004_bib6","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.07.004_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.07.004_bib8","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.07.004_bib9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.stem.2026.04.012","article-title":"Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML","volume":"33","author":"Waclawiczek","year":"2026","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2026.07.004_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and phenotypic correlates of clinical outcomes with venetoclax in acute myeloid leukemia: The GEN-PHEN-VEN study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.07.004_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccell.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.2025030558","article-title":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","volume":"147","author":"Popescu","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1182\/blood-2025-6103","article-title":"F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors","volume":"146","author":"Villaume","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2026.07.004_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx8662","article-title":"Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia","volume":"11","author":"La Vecchia","year":"2025","journal-title":"Sci. Adv."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:18:21Z","timestamp":1786378701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826003132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1535610826003132"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.07.004","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}